HealthTrackRx™ forms JV with Marshall Health & Mountain Health Network
Category: #health  By Pankaj Singh  Date: 2019-03-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

HealthTrackRx™ forms JV with Marshall Health & Mountain Health Network

The newly formed organization will focus on preventing an opioid epidemic in West Virginia and its surrounding regions.

Hospital & healthcare company, HealthTrackRx™ has recently entered into a joint venture (JV) with Marshall Health and Mountain Health Network to offer medical and laboratory services that help healthcare providers to detect and prevent opioid addiction and the misuse of other controlled substances.

Sources close to the move claim that the JV will create a new organization focused on preventing the ongoing opioid epidemic in West Virginia and its surrounding regions. Moreover, it will include a new lab in Huntington that will offer drug testing services to hospitals and physicians and support HealthTrackRx's GuideMed® clinical service.

For the record, GuideMed® allows hospitals and physicians to offer new resources that ensure safe prescribing and monitoring of medication used by people that are treated with opioids and other substances. The program has been used by over 30,000 people, while initial results have demonstrated improved patient compliance and medication use. 

Dr. Doug Brenner, President & CEO, HealthTrackRx, said that the GuideMed® program is focused on helping physicians monitor their patients and properly prescribe pain medications. The program’s objective is to provide a turn-key program that helps confirm safe prescribing, while further supporting enhanced pain treatment results.   

Pleased with the collaboration, Michael Mullins, President & CEO, Mountain Health Network, said that the company is eager to bring these services to its region, and expects it to be vital in providing support to those recovering from substance use disorder. 

He said that the GuideMed® program will offer a framework to help in return-to-work programs and reassure employers in hiring recovery patients. It will also assist physicians to safely prescribe and monitor medications for those requiring treatment for pain management.

Beth L. Hammers, CEO, Marshall Health, said that research and preliminary data from its program have confirmed that comprehensive monitoring offers greater success for its patients to achieve long-term recovery, which will reduce the burden of continuous monitoring by physicians and staff members while still allowing them to track progress and make adjustments throughout the process.



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...